• Heart Failure (HF) in the US is a complex chronic condition with $43B in annual cost.
• There are 960,000 new cases of HF each year with over 6.5M total patients in the US accounting for 8.5% of all cardiac deaths.
• Routine HF care is plagued with high readmission rates of 24% within 1 month and 50%
within 6 months creating the leading cause of hospitalization for patients over age 65.
• The global telehealth market is currently at $71.9B projected to grow to $244B by 2032 with a 12.9% CAGR.
• There are $5.1B Medicare annual losses related to post-acute providers not meeting
quality-of-care requirements for HF with a 37.7% CAGR through 2031 with 75% growth in related software and services.
• We partner with Cardiologists to improve the lives of their patients by overcoming barriers of traditional telemedicine using optimized VPExam virtual care workflows.
• VPExam is the first cardiology focused value-based care company to use technology and continuous care management to deliver peer reviewed publications documenting improved health with reduced readmissions and mortality of cardiovascular patients while significantly reducing cost of care.
o Enables better care for sicker and more complex HF patients.
o Cost effective and portable care to reach high-risk underserved populations in nursing facilities, hospitals, offices, and into the home.
o Customized to each physician with actionable and timely results.
• VPExam Virtual Care for Heart Failure Optimizing Transitions (VPExam QI)
o Revealed 84% moderate clinical modification in care, 40.1% reduction in 30-day rehospitalization, 56.3% reduction in 30-day mortality, 100% compliance with
follow up, and 0% technical errors.
• Growing industry recognition for multiple publications and awards including the Heart Rhythm Society (HRS) Breakthrough Innovation in Cardiovascular Digital Health and Digital Health Hub Foundation 2023 Best in Class Next Generation Telemedicine awards.
